Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fepixnebart - Eli Lilly and Company

Next Previous
X
Search
Drug Profile

Fepixnebart - Eli Lilly and Company

Alternative Names: EPIREG/TGFa MAB - Eli Lilly and Company; LY-3016859; TGF-alpha/epiregulin monoclonal antibody

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Class Analgesics; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor inhibitors; Transforming growth factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Back pain; Neuropathic pain; Pain
  • Phase I/II Diabetic nephropathies

Most Recent Events

  • 11 Nov 2021 Eli Lilly and Company completed a phase II trial in Neuropathic pain in USA and Puerto Rico (IV) (NCT04476108)
  • 04 Oct 2021 Eli Lilly and Company completes a phase-II clinical trials in Back pain (Treatment-experienced, In adults, In the elderly) in USA (IV) (NCT04529096)
  • 26 Aug 2021 Eli Lilly and Company completes a phase II trial in Pain (In patients with osteoarthritis) in Puerto Rico and USA (IV) in August 2021 (NCT04456686)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top